BRIEF published on 10/12/2026 at 07:35, 25 days 7 hours ago Advicenne extends its cash reserves until 2028 Treasury Funding Sales Performance Nephrology Advicenna
BRIEF published on 10/12/2026 at 07:35, 25 days 7 hours ago Advicenne Secures Financial Stability with Extended Runway to 2028 Product Sales Bond Financing Advicenne Financial Runway Share Dilution Risks
PRESS RELEASE published on 10/12/2026 at 07:30, 25 days 7 hours ago Inside Information / Other news releases Advicenne extends financial visibility to 2028 thanks to bond financing and strong sales performance in neurology and nephrology Neurology Bond Financing Advicenne Nephrology Financial Visibility
BRIEF published on 09/28/2026 at 14:40, 1 month 8 days ago Advicenne publishes its monthly voting rights figures Share Capital Voting Rights AMF Share Issuance Advicenna
BRIEF published on 08/31/2026 at 07:05, 2 months 6 days ago Advicenne withdraws the application for registration of ADV7103 in the United States FDA Pharmaceutical Registration Advicenna Sibnayal
PRESS RELEASE published on 08/31/2026 at 07:00, 2 months 6 days ago Inside Information / Other news releases Advicenne voluntarily withdraws NDA for ADV7103 in the USA due to CMC-related work issues. Company hosting French webinar for shareholders. ADV7103 approved in EU, UK, KSA, UAE Pharmaceutical Webinar Advicenne ADV7103 NDA Withdrawal
BRIEF published on 07/16/2026 at 18:40, 3 months 20 days ago Advicenne's Revenue Surge in First Half of 2026 Revenue Growth Advicenne Sibnayal® Likozam® Pharmaceutical Sales
PRESS RELEASE published on 07/16/2026 at 18:35, 3 months 20 days ago Inside Information / Other news releases Advicenne reports significant revenue growth in first half of 2026 driven by Sibnayal® and Likozam® reimbursement in France, ending negative impact of early access rebates. Sales of Sibnayal® and Likozam® increased in volume Revenue Growth France Advicenne Sibnayal® Likozam®
BRIEF published on 07/01/2026 at 17:50, 4 months 4 days ago Unlimited renewal of the marketing authorization for Sibnayal® by Advicenne in the United Kingdom United Kingdom Advicenna Sibnayal Rare Kidney Diseases Marketing Authorization Renewal
BRIEF published on 06/22/2026 at 19:12, 4 months 13 days ago Advicenne Secures Financing to Q2 2027 with New Bond Issue Strategic Development Bond Financing FDA Registration Advicenne Rare Kidney Diseases
Published on 11/06/2026 at 13:00, 1 hour 41 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 hours 11 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 hours 11 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 9 hours 26 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 14:36, 4 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 11/05/2026 at 18:21, 20 hours 19 minutes ago Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:45, 20 hours 56 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 21 hours 11 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
